Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya

Nav

General Info

Geography

Kenya (KEN)

Uganda (UGA)

Coverage type

Country

Time period covered

01/2007 - 12/2011

Data type

Scientific literature

Keywords

HIV and AIDS, Health care costs, Health care expenditures

Citation

Authors

Simpson KN, Baran RW, Kirbach SE, Dietz B

Journal

Value Health

Volume

Issue

Pages

1048-54

Publication year

2011

Suggested citation

Simpson KN, Baran RW, Kirbach SE, Dietz B. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011; 14(8): 1048-54.

DOI

10.1016/j.jval.2011.06.011

PMID

22152173

GHDx Entry last modified on: Apr 10, 2023

Header sites

Search form

Main menu

Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya

Nav